ELA026
Phase 3Small molecule
ELA026 is one of 9 small molecule programs targeting T-cell Malignancies. It is currently in Phase 3.
2
Indications
3
Total Trials
2
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
10 competitors in Histiocytosis
#DrugCompanyPhaseTrials
1Jakafi
IncyteApproved
Vepesid
AAvyxa
Approved
Decadron
AAspen Global Incorporated
Approved
Leustatin
EMD SeronoApproved
Alkeran
AApotex Inc.
Approved
Zelboraf
CConrado Roberto Hoffmann Filho
Phase 2
ELA026
EElectra Therapeutics Inc.
Phase 3
Prevymis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
EBV-TCR-T Cells
FFujian Cancer Hospital
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Histiocytosis1 trial
Tics1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ELA026. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- EElectra Therapeutics Inc.